Cargando…

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

AIMS/HYPOTHESIS: The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function decline in type 2 diabetes. The aim of this study was to assess the effect of the SGLT2 inhibitor canagliflozin on biomarkers for progression of diabetic kidney disease (DKD). MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heerspink, Hiddo J. L., Perco, Paul, Mulder, Skander, Leierer, Johannes, Hansen, Michael K., Heinzel, Andreas, Mayer, Gert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560022/ https://www.ncbi.nlm.nih.gov/pubmed/31001673 http://dx.doi.org/10.1007/s00125-019-4859-4

Ejemplares similares

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Validation of systems biology derived molecular markers of renal donor organ status associated with long term allograft function
por: Perco, Paul, et al.
Publicado: (2018)

Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study
por: Denicolò, Sara, et al.
Publicado: (2022)

Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease
por: Leierer, Johannes, et al.
Publicado: (2021)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Assessment of Fibrinogen-like 2 (FGL2) in Human Chronic Kidney Disease through Transcriptomics Data Analysis
por: Denicolò, Sara, et al.
Publicado: (2022)

From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action
por: Heinzel, Andreas, et al.
Publicado: (2014)

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles
por: Koppelstaetter, Christian, et al.
Publicado: (2019)

A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases
por: Neuwirt, Hannes, et al.
Publicado: (2014)

Increased Renal Versican Expression Is Associated with Progression of Chronic Kidney Disease
por: Rudnicki, Michael, et al.
Publicado: (2012)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
por: Ali, Amr, et al.
Publicado: (2023)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease
por: Gregorich, Mariella, et al.
Publicado: (2023)

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
por: Mulder, Skander, et al.
Publicado: (2020)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Shiba, Kumiko, et al.
Publicado: (2018)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

SGLT2 Inhibitors—A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling
por: Yagi, Takashi, et al.
Publicado: (2022)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes
por: Pena, Michelle J., et al.
Publicado: (2015)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
por: Koutentakis, Michail, et al.
Publicado: (2023)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
por: Jojima, Teruo, et al.
Publicado: (2019)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

GMP Compliant Synthesis of [(18)F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2
por: van der Hoek, Sjoukje, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l330maqpu7om9vu8vnisrja4qb